Anjali Vaidya, MD, FACC, FASE, FACP, Co-Director of the Pulmonary Hypertension, Right Heart Failure & Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Temple University Hospital, provided perspective to MedPage Today on findings related to adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients, which helped delay serious outcomes in the ZENITH trial. The findings were presented at the American College of Cardiology annual meeting and published in the New England Journal of Medicine.
Weather Alert: A major winter storm is likely to impact the Philadelphia region this weekend into Monday. Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH